Blog
RSS FeedPosted by Michael Wonder on 10 Sep 2024
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer
29 August 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Sep 2024
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with unresectable advanced, claudin 18.2 positive HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
9 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Sep 2024
Fedratinib dihydrochloride monohydrate for the treatment of patients with disease-related splenomegaly or symptoms in myelofibrosis
6 September 2024 - The Department of Health and Social Care has asked NICE to review its guidance on the ...
Posted by Michael Wonder on 06 Sep 2024
Pegzilarginase for the treatment of patients with arginase-1 deficiency
6 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Sep 2024
Adults with von Hippel-Lindau disease to benefit from new treatment
5 September 2024 - NICE has recommended belzutifan for some adults with von Hippel-Lindau disease, in final draft guidance, which could ...
Posted by Michael Wonder on 04 Sep 2024
Zanubrutinib for the treatment of patients with marginal zone lymphoma after anti-CD20-based treatment
4 September 2024 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 04 Sep 2024
Iptacopan hydrochloride for the treatment of patients with paroxysmal nocturnal haemoglobinuria
4 September 2024 - NICE has published final evidence-based recommendations on the use of iptacopan hydrochloride (Fabhalta) for the treatment ...
Posted by Michael Wonder on 04 Sep 2024
Vibegron for the treatment of patients with symptoms of overactive bladder syndrome
4 September 2024 - NICE has published final evidence-based recommendations on the use of vibegron (Obgemsa) for the treatment of ...
Posted by Michael Wonder on 29 Aug 2024
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- ...
Posted by Michael Wonder on 25 Aug 2024
Risankizumab for the treatment of patients with moderately to severely active ulcerative colitis
23 August 2024 - NICE has published final evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of ...
Posted by Michael Wonder on 22 Aug 2024
Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS
22 August 2024 - Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, ...
Posted by Michael Wonder on 14 Aug 2024
Linzagolix choline for the treatment of patients with moderate to severe symptoms of uterine fibroids (final guidance)
14 August 2024 - NICE has published final evidence-based recommendations on the use of linzagolix choline (Yselty) for the treatment ...
Posted by Michael Wonder on 14 Aug 2024
Relugolix for the treatment of patients with hormone sensitive prostate cancer
14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of ...
Posted by Michael Wonder on 10 Aug 2024
Two new treatment options for incurable blood cancer assessed
9 August 2024 - We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, ...
Posted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the ...